• On 27 June 2026, Ultragenyx Pharmaceutical Inc. was removed from larger-cap Russell 1000 and Midcap indices and simultaneously added to the Russell 2000, related growth and value benchmarks, and several Russell value indices, reflecting a broad reclassification within the Russell index family.
• This reshuffling across size and style indices can materially influence trading flows as index-tracking and benchmark-aware investors adjust their portfolios to the new compositions.
• With Ultragenyx now shifted into the Russell 2000 and related value and growth benchmarks, we'll examine how this index migration influences its investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

Ultragenyx Pharmaceutical Investment Narrative Recap

To own Ultragenyx, you have to believe its rare disease pipeline can turn today’s heavy losses and thin cash runway into a sustainable commercial franchise, with upcoming FDA decisions on UX111 and DTX401 as key near term swing factors. The Russell migration itself does not change those fundamentals, but it can shift who owns the stock and how volatile trading feels around these regulatory catalysts and the ongoing risk of further dilution.

Among recent announcements, the FDA’s acceptance of the DTX401 BLA for Glycogen Storage Disease Type Ia, with an August 23, 2026 PDUFA date, looks particularly important. This potential approval sits at the heart of the company’s 2026 revenue guidance of US$730 million to US$760 million and its stated goal of reaching profitability in 2027, both of which matter far more to the long term story than any index reshuffle.

Yet behind the potential for new approvals and revenue growth, investors should be aware of the company’s high cash burn and less than one year of cash runway...

Ultragenyx Pharmaceutical's narrative projects $1.3 billion revenue and $114.0 million earnings by 2029.

Uncover how Ultragenyx Pharmaceutical's forecasts yield a $52.05 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were projecting Ultragenyx could reach about US$1.6 billion in revenue and US$335 million in earnings by 2029, which is far more upbeat than consensus. With the Russell index reclassification and heavy dependence on a small set of gene therapy programs, you can see how opinions differ sharply and why this latest news might eventually shift both the bullish and cautious narratives.

Explore 3 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be worth just $52.05!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Ultragenyx Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ultragenyx Pharmaceutical's overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.